-
NEJM: Cases of Acute Myeloid Leukemia after Gene Therapy for Sickle Cell Disease
Time of Update: 2021-12-26
Analysis of the patient’s peripheral blood samples revealed that the mother cell contained a BB305 lentiviral vector insertion site .
Acute Myeloid Leukemia Case after Gene Therapy for Sickle Cell Disease.
Acute Myeloid Leukemia Case after Gene Therapy for Sickle Cell Disease.
-
What should I do if the red blood cell agglutination cannot be corrected by the warm bath?
Time of Update: 2021-12-26
So the specimens were tested after being heated at 37°C for 30 minutes, and the results were as follows:It can be seen from the results that although MCH and MCHC have decreased, the red blood cell histogram is still abnormal, and red blood cell agglutination has not been corrected .
-
NEJM: Daprodustat for treatment of anemia in chronic kidney disease without dialysis
Time of Update: 2021-12-26
The primary endpoint of the study was the average change in the patient’s hemoglobin level from baseline examination to weeks 28-52, and the first major adverse cardiovascular event (MACE; death from any cause, non-fatal myocardial infarction, or non-fatal stroke) .
-
blood: HLA association, HLA expression of somatic cell loss and clinical results in immune aplastic anemia.
Time of Update: 2021-12-26
A research team examined the somatic cell loss of HLA class I alleles and correlated HLA genotypes related to HLA loss and mutation with the clinical manifestations and results of 544 AA patients after immunosuppressive treatment .
-
BJH: Patient report results of relapsed/refractory multiple myeloma treated with meflufen plus dexamethasone
Time of Update: 2021-12-26
17 CI, confidence interval; EORTC QLQ-C30, core 30 of the European Organization for Cancer Research and Treatment Quality of Life Questionnaire; LS, least squares method; QoL, quality of life 17 17 17 Figure 3: Proportion of patients with a significant improvement from baseline on the EORTC QLQ-C30 scale throughout the treatment cycle .
-
Leukemia: Long-term survival rate of AML patients 70 years and older after intensive chemotherapy or hypomethylation drugs
Time of Update: 2021-12-26
In general, the main results of the study indicate that the evaluation of new alternative therapies should take long-term survival as a relevant clinical endpoint in order to have a clear understanding of the benefits of long-term low-intensity therapy compared with short-term IC, even in elderly subjects The same is true among those .
-
NEJM: Daprodustat treats anemia in chronic kidney disease undergoing dialysis
Time of Update: 2021-12-26
The primary endpoint of the study was the average change in hemoglobin levels from baseline examination to weeks 28-52 and the first major adverse cardiovascular event (combination of death from any cause, non-fatal myocardial infarction, or non-fatal stroke) .
-
BJH: Identification of high-risk patients with secondary extramedullary multiple myeloma
Time of Update: 2021-12-26
According to unsatisfactory treatment results, it is clinically necessary to diagnose patients with a high risk of developing secondary EMD as soon as possible .
According to unsatisfactory treatment results, it is clinically necessary to diagnose patients with a high risk of developing secondary EMD as soon as possible .
-
BJH: First use of anti-VWF nanobody caplacizumab to treat iTTP during pregnancy
Time of Update: 2021-12-24
Figure: (A) Timeline of platelets, LDH levels, ADAMTS13 activity and anti-ADAMTS13 antibodies related to disease onset (day 0) and treatment .
Figure: (A) Timeline of platelets, LDH levels, ADAMTS13 activity and anti-ADAMTS13 antibodies related to disease onset (day 0) and treatment .
-
Mao Amin's husband Xie Zhikun died of a heart attack, experts appeal
Time of Update: 2021-12-24
Xie Zhikun"The causes of sudden death are complex.
In addition, myocardial infarction is one of the most common causes of sudden death.
From April 1995 to June 2000, Xie Zhikun served as the chairman of Zhongzhi Enterprise Group Co.
-
Hyperkalemia drug Veltassa shows benefits for patients with heart failure
Time of Update: 2021-12-24
diabetesVifor Pharma reported on Tuesday that its hyperkalemia treatment Veltassa (patiromer) reached the primary end point of the Phase IIIb trial (DIAMOND study), which helps to control the serum potassium levels of patients with heart failure .
-
Treatment strategies for high-risk MDS patients from an international perspective
Time of Update: 2021-12-08
The results of several retrospective studies have shown that HSCT can improve the survival benefit of patients with high-risk MDS, and this benefit has been recognized .
Although compared with alternative or supportive treatment, HMA can improve treatment response and prolong survival, but the prognosis of patients is still not optimal .
-
Management of infection in patients with CLL
Time of Update: 2021-12-08
Although the application of chemoimmunotherapy and targeted therapies (BTK inhibitors and BCL-2 inhibitors) has improved the prognosis of CLL patients and can extend the overall survival (OS), in the past forty years, deaths caused by infections The rate has not decreased .
-
The effect of radiotherapy on patients with advanced HL who have been treated with the ABVD regimen and have large mass lesions: the final results of the FIL HD0801 study are announced
Time of Update: 2021-12-08
In the third phase of the study, patients who achieved CMR after 2 and 6 cycles of ABVD treatment and had large mass lesions (maximum diameter ≥5cm) were randomly assigned to receive consolidation radiotherapy (dose 30Gy) or observation (OBS) .
-
Reindeer Medical's full-human dual-target CAR-T therapy phase I/II registration clinical study completed the first patient enrollment and single-source doctor Mai Meng broke the news
Time of Update: 2021-12-08
Recent popular reports from Yimaike ★ Invitation Letter 2021 CSGCT Gene and Cell Therapy Medical Summit will be held in Shanghai ★ Zhang Feng Lianchuang Beam Company’s first IND application approved
-
The new indication for Daratuomab injection (Zhao Ke®) was approved, adding another weapon to the first-line treatment of multiple myeloma!
Time of Update: 2021-12-07
After Zhaoke® was approved for second-line indications in April 2021, Zhaoke® was again approved for new indications in November 2021-daratumomab combined with lenalidomide and dexamethasone (DRd) or combined The combination of bortezomib, melphalan and prednisone (DVMP) for the treatment of newly diagnosed multiple myeloma (NDMM) adult patients who are not suitable for autologous stem cell transplantation has once again revolutionized the domestic multiple myeloma treatment pattern .
-
Bispecific antibody epcoritamab in the treatment of recurrent lymphoma
Time of Update: 2021-12-07
Comment In this early clinical trial, epcoritamab achieved a high remission rate for patients, so there is an additional bispecific antibody under investigation for the treatment of relapsed/refractory B-cell lymphoma .
-
Even more powerful!
Time of Update: 2021-12-07
In this investment, up to US$150 million will be used to develop and commercialize obecabtagene autoleucel (Obe-cel), a targeted CD19 CAR-T cell therapy for the treatment of acute lymphoblastic leukemia .
-
MMF combined with glucocorticoids is expected to increase the remission rate of newly diagnosed ITP patients
Time of Update: 2021-12-07
Research method The FLIGHT trial is a multi-center, open-label, randomized, controlled clinical study comparing MMF combined with glucocorticoid and glucocorticoid alone as the first-line treatment of ITP .
-
[Lymphoma micro course 2021ASH first look] After IRV, different courses of treatment are followed according to risk stratification. R-HyperCVAD/MTX is used for young newly-treated MCL patients
Time of Update: 2021-12-07
Therefore, they designed the Window 2 study to evaluate the use of IRV in young newly-treated MCL patients after the use of IRV according to risk stratification and sequential different courses of treatment R- HyperCVAD/MTX is used as a consolidation therapy for the safety and efficacy.
